Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.
Cyclosporin (7.5 mg/kg daily) was given to 8 AIDS patients for 17-66 days and to 25 HIV-seropositive non-AIDS patients, 15 with stage II (T4 cells/microliter greater than or equal to 300, less than 600) and 10 with stage III (T4/microliter less than 300), for 3-6 months with the hypothesis that the drug could inhibit both HIV replication and the potential autoimmune component of HIV disease. A sustained increase over 600 T4/microliter occurred in 7 patients with stage II and 1 with stage III. T8 cells significantly decreased in most patients and lymphadenopathy disappeared in 14/16. After cyclosporin withdrawal T4 and T8 cells as well as lymphadenopathy returned to pretreatment status. Cyclosporin side effects (hypertension, creatinine increase, and anemia) were moderate and reversible. These results might stimulate biological research as well as clinical trials with cyclosporin in selected groups of HIV-seropositive subjects with the aim of delaying or preventing AIDS occurrence.
Andrieu
J M
JM
Laennec HIV Study Group, Laennec Hospital, University of Paris V, France.
Even
P
P
Venet
A
A
Tourani
J M
JM
Stern
M
M
Lowenstein
W
W
Audroin
C
C
Eme
D
D
Masson
D
D
Sors
H
H
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D001772:Blood Cell Count / Q000187:drug effects; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000145:classification / Q000187:drug effects*; D013997:Time Factors
D000945:Antigens, Differentiation, T-Lymphocyte; D003524:Cyclosporins